Lumos Pharma

Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, focused on developing and commercializing therapeutics for severe, rare, and genetic diseases. Its lead candidate, LUM-201, is an oral growth hormone-stimulating small molecule currently in Phase 2 clinical trials for pediatric growth hormone deficiency. The company also has a licensing agreement with Ellipses Pharma Limited to develop and commercialize nanoparticle formulations for oncology indications. Additionally, Lumos Pharma is working on treatments for Creatine Transporter Deficiency, leveraging technology from the University of Cincinnati and collaborating with key opinion leaders and the U.S. National Institutes of Health. Founded in 2011, Lumos Pharma engages in partnerships with pharmaceutical companies and contracts with manufacturing organizations to advance its research and development efforts.